Hepatocellular Carcinoma (HCC) does not only seriously endanger the physical and mental health of patients, but also poses a significant challenge to public health. The majority of patients diagnosed with advanced HCC are not eligible to receive radical treatment, such as surgery, therefore targeted molecular therapy (i.e. oral protein kinase inhibitors) or the precision chemotherapy (i.e. transarterial chemoembolization or the long-acting sustained-release formulation of antitumor agents) is the main therapeutic strategy effective for advanced HCC.
Although molecular targeted drugs, such as Sorafenib, can delay the progression of HCC disease and prolong patient survival, they still present a number of challenges: (1) Sorafenib treatment in advanced HCC patients. There are individual differences in the initial sensitivity of patients to Sorafenib, and most patients who initially respond well to Sorafenib will eventually develop drug tolerance as the treatment progresses; (2) Existing treatment strategies (e.g. Sorafenib treatment requires oral high-dose of [800mg per day]) can cause serious side effects while treating cancer; (3) Recently, Lenvatinib has been approved as a first-line therapy, and Regorafenib as a second-line therapy, with hope that there may be further reports reviewing their tolerance in the future. (4) HCC targeted drug therapy remains costly. Considering these challenges, it is necessary to seek novel therapeutic strategies for HCC treatment, as well as for intrahepatic cholangiocarcinoma (ICC).
In this Research Topic, we aim to provide an overview of the recent progress around HCC treatment, especially HCC-ICC-related drug therapy and the molecular mechanism of drug resistance, encompassing relevant basic and translational studies.
We welcome submission of Original Research, Mini Review and Review articles focusing on the sub-topics below:
• Molecular mechanisms related to the HCC or ICC, i.e. the molecular mechanism of antitumor drug resistance, proliferation or metastasis
• Small molecule kinase inhibitors or chemotherapeutic drugs with new structures for HCC or ICC treatment
• New long-acting and sustained-release anti-tumor drugs on HCC or ICC
• Nanomedicine and materials for HCC or ICC treatment
• Molecular markers based on novel clinical laboratory technology
• Clinical diagnosis, treatment and imaging of liver space-occupying lesions
• Progress in intrahepatic cholangiocarcinoma treatment and research
• Clinical application of surgical robots
Please note: for manuscripts submitted in consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for Frontiers in Oncology, Pharmacology of Anti-Cancer Drugs section and will not be accepted as part of this Research Topic in the said section.
Hepatocellular Carcinoma (HCC) does not only seriously endanger the physical and mental health of patients, but also poses a significant challenge to public health. The majority of patients diagnosed with advanced HCC are not eligible to receive radical treatment, such as surgery, therefore targeted molecular therapy (i.e. oral protein kinase inhibitors) or the precision chemotherapy (i.e. transarterial chemoembolization or the long-acting sustained-release formulation of antitumor agents) is the main therapeutic strategy effective for advanced HCC.
Although molecular targeted drugs, such as Sorafenib, can delay the progression of HCC disease and prolong patient survival, they still present a number of challenges: (1) Sorafenib treatment in advanced HCC patients. There are individual differences in the initial sensitivity of patients to Sorafenib, and most patients who initially respond well to Sorafenib will eventually develop drug tolerance as the treatment progresses; (2) Existing treatment strategies (e.g. Sorafenib treatment requires oral high-dose of [800mg per day]) can cause serious side effects while treating cancer; (3) Recently, Lenvatinib has been approved as a first-line therapy, and Regorafenib as a second-line therapy, with hope that there may be further reports reviewing their tolerance in the future. (4) HCC targeted drug therapy remains costly. Considering these challenges, it is necessary to seek novel therapeutic strategies for HCC treatment, as well as for intrahepatic cholangiocarcinoma (ICC).
In this Research Topic, we aim to provide an overview of the recent progress around HCC treatment, especially HCC-ICC-related drug therapy and the molecular mechanism of drug resistance, encompassing relevant basic and translational studies.
We welcome submission of Original Research, Mini Review and Review articles focusing on the sub-topics below:
• Molecular mechanisms related to the HCC or ICC, i.e. the molecular mechanism of antitumor drug resistance, proliferation or metastasis
• Small molecule kinase inhibitors or chemotherapeutic drugs with new structures for HCC or ICC treatment
• New long-acting and sustained-release anti-tumor drugs on HCC or ICC
• Nanomedicine and materials for HCC or ICC treatment
• Molecular markers based on novel clinical laboratory technology
• Clinical diagnosis, treatment and imaging of liver space-occupying lesions
• Progress in intrahepatic cholangiocarcinoma treatment and research
• Clinical application of surgical robots
Please note: for manuscripts submitted in consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for Frontiers in Oncology, Pharmacology of Anti-Cancer Drugs section and will not be accepted as part of this Research Topic in the said section.
